¿Estás buscando esta información en español?

2EyesVision lanza SimVis Gekko2, el simulador visual que permite al paciente experimentar su futura visión antes de operarse:

 

2EyesVision Launches SimVis Gekko2, the visual simulator that allows patients to experience their future vision before surgery

• The Spanish startup introduces a pioneering technology that, for the first time, allows surgeons to choose the best lens for each patient.
• The device enables a personalized recommendation process tailored to the patient's visual profile and improves communication with the ophthalmologist.

Madrid, Spain – Technology company 2EyesVision announces the international launch of SimVis Gekko2, a groundbreaking device that allows patients to realistically experience how they will see after cataract or presbyopia surgery, depending on the selected intraocular lens. Developed in Spain, this technology enhances the preoperative experience and strengthens communication between professionals and patients.

SimVis Gekko2 uses a programmable fluidic lens to project the optical effect of different intraocular lens models into the patient’s eye. Until now, patients could only imagine what their vision would be like post-surgery based on explanations from their ophthalmologist. For the first time, they can directly experience the visual effects of each option. This helps align expectations, improve understanding of the treatment, and enrich clinical conversations with a visual, realistic, and intuitive tool. The technology has sparked wide interest within the ophthalmology community following its pre-launch at ESCRS—the European Congress of Refractive and Cataract Surgery—and FacoElche 2025—one of the most prominent Spanish-speaking ophthalmology events. Following regulatory approvals, SimVis Gekko2 is now available on the market, with the first units already sold internationally.

 

Validated innovation ready to scale

SimVis Gekko2 is the result of over a decade of research, supported by more than 25 scientific publications and protected by five families of international patents. Its design was developed in collaboration with Spark Design & Innovation (Netherlands), a firm specializing in ergonomics and user experience. The technology development was led by 2EyesVision’s R&D team in close collaboration with the Institute of Optics at the Spanish National Research Council (CSIC).

“SimVis Gekko2 represents a decisive step towards personalized medicine in ophthalmology,” says Carlos Dorronsoro, CEO and co-founder of 2EyesVision. “Allowing patients to experience their future vision builds trust and helps professionals make better decisions.”

The launch coincides with the appointment of Máximo Gómez, former General Manager of Johnson & Johnson Vision Iberia, as Head of Global Commercial Strategy. Additionally, the company has opened a new investment round led by Bullnet Capital and INNVIERTE-CDTI, with support from ENISA, to accelerate its international expansion.

 

Feedback from early users

SimVis Gekko2 was tested in leading clinics across several countries before its official launch. Among other new features, the device includes a Pupil Monitoring System that facilitates automatic alignment, streamlining the simulation process and improving its stability. Its use in patients with moderate cataracts is supported by recent scientific studies.

Ophthalmologists using the device highlight its role in helping patients better understand the various visual correction options, boosting their confidence and enabling more personalized lens selection based on their needs and lifestyle. After surgery, many patients report that their final vision matches what they experienced during the simulation.

Dr. Joaquín Fernández (QVision, Almería) notes that the new device will support their commitment to patient satisfaction: “SimVis changes the patient experience, allowing them to express opinions about what they perceive. This information is crucial and helps us align with their needs and preferences.”

Dr. Alberto de Castro (Clínica de Castro, Valencia) adds: “This cutting-edge tool helps our patients better understand the differences between monofocal lenses and the various multifocal options, enabling more informed decisions based on their visual experience and preferences, as optical concepts can be hard to imagine.”

Dr. Carlos Gutiérrez Amorós (Clínica Gutiérrez Amorós, A Coruña) emphasizes patient feedback post-surgery: “The feedback is very positive. Patients who underwent the simulation tell us after the surgery that they achieved the vision they expected.”

 

About 2EyesVision

Founded as a technology-based company originating from the Institute of Optics of the CSIC, 2EyesVision develops innovative solutions in the field of ophthalmology. Its SimVis Gekko2 device helps ophthalmologists select the most suitable intraocular lens for each patient.

More information about SimVis Gekko2

From live demos to global collaboration, SimVis Gekko took center stage at APAO2025 in New Delhi—shaping the future of patient-centered IOL selection.

New Delhi, India – The APAO2025 Congress in New Delhi marked a milestone for 2EyesVision, with SimVis Gekko featured in a high-profile hot-topic session and key symposiums addressing the future of presbyopia treatment.

In the session titled “Looking for a Solution to Presbyopia: What Options Do We Have Today?”, Helena Prior Filipe and Krueger Ronald led live simulations using SimVis Gekko. Attendees witnessed in real time how the device is reshaping preoperative IOL selection, offering a precise, interactive, and patient-specific approach to visual planning.

Beyond the live demonstrations, 2EyesVision also participated in a compelling symposium alongside Prof. Moore (Belfast) and Dr. Ashraf Armia (Glasgow, UK), focusing on optimal IOL selection, the role of patient education, and the importance of clinician–patient partnership.

As part of this session, Candela Rodríguez presented the talk:

“Artis Symbiose and SimVis Gekko – Redefining Vision Experience,”
highlighting how SimVis enables patients to preview the vision offered by premium IOLs, such as the Artis Symbiose by Cristalens International, before surgery.

These discussions underscored SimVis Gekko’s value not only as an optical innovation, but as a powerful educational and communication tool in refractive and cataract surgery.

If you’re attending APAO2025, don’t miss your chance to experience SimVis Gekko firsthand at booth SP246. It’s not just innovation—it’s a new way to envision the future of presbyopia solutions.

 

Are you exploring smarter ways to guide IOL decisions for presbyopia patients?

SimVis Gekko is helping practices worldwide personalize care and enhance surgical planning. Contact our team to discover how it can support your clinical goals.